Hypersensitivity. Therapy requires FBC (Hb & WBC), & platelet count, assessment of liver (ALT & AST) & renal (serum creatinine & urea) functions & electrolytes (K, Mg, Ca). Patients w/ known risk factors for prolongation of QT interval eg, congenital long QT syndrome, a known history of acquired QTc prolongation, medicinal products that can prolong QTc interval & hypokalaemia; known or suspected heart disease. Regularly monitor during treatment (eg, ECG or echocardiography) for evidence of CV effects that may require further CV exam & investigation. Hypokalaemia or hypomagnesaemia must be corrected prior to administration. Patients of underlying cardiopulmonary disease should be evaluated prior to initiating & during therapy. Concomitant use w/ other PDE III inhibitors eg, milrinone, amrinone, enoximone, olprinone & cilostazol is not recommended. Patients w/ rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. May impair ability to drive or operate heavy machinery. Not recommended in patients w/ elevated transaminases (>5x ULN). Assess patients w/ renal impairment before treatment is commenced, Not recommended during pregnancy. Lactation. Women of child-bearing potential should use adequate birth-control measures during treatment. Childn.
Sign Out
